Mogroside V Protects against Hepatic Steatosis in Mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation

Table 2

Physiological and biochemical parameters following 10-week administration of MV in HFD-fed C57BL/6 mice.

Parameter	Control	HFD	Low-dose MV	Medium-dose MV	High-dose MV
Body weight (g)	25.27 ± 0.40	40.82 ± 1.97	37.24 ± 1.82	36.40 ± 2.33	33.12 ± 1.97
Liver weight (g/Kg b.w.)	41.69 ± 1.09	31.38 ± 0.76	31.40 ± 0.79	32.63 ± 0.52	34.88 ± 1.12
NEFA (μmol/L)	334.6 ± 13.8	500.2 ± 19.4	458.0 ± 21.6	408.9 ± 11.4	409.0 ± 9.0
TG (mmol/L)	0.79 ± 0.06	1.11 ± 0.07	1.09 ± 0.07	1.07 ± 0.03	0.93 ± 0.05
T-CHO (mmol/L)	2.54 ± 0.20	5.76 ± 0.35	5.46 ± 0.22	5.50 ± 0.35	4.51 ± 0.32
Blood glucose (mmol/L)	3.88 ± 0.26	6.86 ± 0.32	5.9 ± 0.29	5.09 ± 0.31	4.11 ± 0.44
Insulin (mIU/L)	3.91 ± 0.24	5.46 ± 0.21	4.88 ± 0.14	4.72 ± 0.22	4.27 ± 0.23
HOMA-IR	0.66 ± 0.04	1.67 ± 0.14	1.29 ± 0.07	1.06 ± 0.07	0.78 ± 0.10
AST (U/L)	15.87 ± 1.06	22.34 ± 2.79	23.25 ± 1.87	20.30 ± 2.73	18.76 ± 2.19
ALT (U/L)	20.41 ± 1.27	31.78 ± 3.42	25.67 ± 1.33	19.96 ± 2.98	18.68 ± 2.08

Data are expressed as the mean ± SEM (n = 9). vs. control; vs. control; vs. control; vs. HFD; vs. HFD; vs. HFD.